Merck_ad_proof.qxp 21/7/08 03:30 Page 5
Only one cervical cancer
vaccine also helps protect
against genital warts
GARDASIL—vaccinate girls and young women 9 to 26 years of age against
a
HPV 6–, 11–, 16–, and 18–related cervical cancer and genital warts
GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer,
precancerous or dysplastic lesions, and genital warts caused by HPV Types 6, 11, 16, and 18.
Select safety information
GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the
excipients of the vaccine.
GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should
continue to undergo screening per standard of care.
GARDASIL is not recommended for use in pregnant women.
Vaccination with GARDASIL may not result in protection in all vaccine recipients.
GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer;
cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of
at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness.
In addition, common postmarketing reports include vomiting and syncope.
Please read Brief Summary of Prescribing Information on adjacent page.
a
HPV=human papillomavirus.
GARDASIL is a registered trademark
of Merck & Co., Inc.
Copyright © 2008 Merck & Co., Inc.
All rights reserved. 20850012(6)(307)-GRD
M0080_20850012(6).indd 1 5/28/08 10:33:35 AM
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116